Efficacy

Zynlonta (loncastuximab tesirine-lpyl) for Lymphoma

Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The efficacy of Zynlonta was evaluated in a multicenter, single-arm, open-label clinical trial known as LOTIS-2. The study demonstrated that Zynlonta could achieve a significant therapeutic effect in a population of patients who had previously undergone multiple lines of therapy, which often leaves them with limited treatment options.

In the LOTIS-2 trial, the overall response rate (ORR) was observed to be around 48.3%, with a complete response (CR) rate of 24.1%. The median duration of response (DOR) for those who achieved a CR was not reached, indicating a potentially durable response for some patients. These results suggest that Zynlonta offers a promising therapeutic option for patients with difficult-to-treat large B-cell lymphoma, particularly in the relapsed or refractory setting.

Epkinly (epcoritamab-bysp) for Lymphoma

Epkinly (epcoritamab-bysp) is an investigational bispecific antibody targeting both CD3 on T-cells and CD20 on B-cells, designed to engage the body’s immune system to fight B-cell lymphomas. While Epkinly is not yet approved for any indications, ongoing clinical trials are assessing its efficacy in various types of B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The mechanism of action of epcoritamab involves redirecting T-cells to induce the killing of CD20-expressing B-cells, which is a hallmark of many B-cell lymphomas.

Preliminary data from ongoing clinical trials have shown encouraging results. For instance, in a phase 1/2 trial, epcoritamab has demonstrated a manageable safety profile and notable efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The reported ORR across different lymphoma subtypes was promising, with some patients achieving complete remission. However, it is important to note that these results are from early-phase trials, and further research is required to confirm the efficacy and safety of Epkinly in larger, more diverse patient populations.